Evolving Mechanisms, Enduring Goals: NICHD OPPTB Support for the Science of Therapeutics in Pregnancy and Childhood (2004–Present)
- 1Obstetric and Pediatric Pharmacology and Therapeutics Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda Maryland USA
Abstract
The Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH) was formed in 2004 following the enactment of the Best Pharmaceuticals for Children Act (BPCA) of 2002, in recognition of the unique research needs of studying therapeutics in pregnant women and in children of all ages. During the past two decades, the branch has supported basic, translational, and clinical research in maternal and pediatric therapeutics, including the application of emerging technologies and training and career-development activities. Its portfolio has evolved in response to scientific, regulatory, and legislative changes and has expanded to include pediatric medical devices and a stronger focus on lactation pharmacology. This mini-review describes the evolution of these programs, selected contributions, remaining limitations, and future scientific priorities.
Related
- The evolving landscape of fungal keratitis: from emerging pathogens to precision diagnostics and novel therapeutics
- Evolving skin cancer therapeutics: molecular and genetic drivers, immunotherapy challenges, and advances in nanogel-based nanomedicine
- Exclusion by Design: Regulatory Reform and Evolving Frameworks for Clinical Trials in Pregnancy
- Adverse childhood experiences are linked to pre-pregnancy stressful life events across generations
- Alzheimer's Disease Neurofibrillary Pathophysiology: PTPRD- and Flavonol-Modified Mechanisms, Prevention and Therapeutics.
BibTeX
@article{fabiyi2026evolving,
title = {{Evolving Mechanisms, Enduring Goals: NICHD OPPTB Support for the Science of Therapeutics in Pregnancy and Childhood (2004–Present)}},
author = {Camille A. Fabiyi and Aaron C. Pawlyk and Gabriela Piatkowski and Antonello Pileggi and Zhaoxia Ren and Lesly A. Samedy‐Bates and Perdita Taylor‐Zapata},
journal = {Clinical Pharmacology and Therapeutics},
year = {2026},
month = nov,
doi = {10.1002/cpt.70526},
url = {https://doi.org/10.1002/cpt.70526},
note = {Public domain},
}
RIS
TY - JOUR
TI - Evolving Mechanisms, Enduring Goals: NICHD OPPTB Support for the Science of Therapeutics in Pregnancy and Childhood (2004–Present)
AU - Camille A. Fabiyi
AU - Aaron C. Pawlyk
AU - Gabriela Piatkowski
AU - Antonello Pileggi
AU - Zhaoxia Ren
AU - Lesly A. Samedy‐Bates
AU - Perdita Taylor‐Zapata
PY - 2026
DA - 2026/11/11
JO - Clinical Pharmacology and Therapeutics
DO - 10.1002/cpt.70526
UR - https://doi.org/10.1002/cpt.70526
AB - The Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH) was formed in 2004 following the enactment of the Best Pharmaceuticals for Children Act (BPCA) of 2002, in recognition of the unique research needs of studying therapeutics in pregnant women and in children of all ages. During the past two decades, the branch has supported basic, translational, and clinical research in maternal and pediatric therapeutics, including the application of emerging technologies and training and career-development activities. Its portfolio has evolved in response to scientific, regulatory, and legislative changes and has expanded to include pediatric medical devices and a stronger focus on lactation pharmacology. This mini-review describes the evolution of these programs, selected contributions, remaining limitations, and future scientific priorities.
SN - 0009-9236
SN - 1532-6535
ER -